Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837990 | 0.95 | ADORA2B (0.52) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL837398 | 0.95 | ADORA2B (0.52) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL836803 | 0.93 | ADORA2B (0.49) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL3123746 | 0.93 | ADORA2B (0.52) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL14618819 | 0.86 | PDE4A (0.57) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL3118639 | 0.86 | ADORA2B (0.47) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL3119443 | 0.85 | SIRT1 (0.54) | ADORA1ADORA2BADORA2AADORA3SIRT1 | |
| SCHEMBL837104 | 0.84 | ADORA1 (0.47) | ADORA1SIRT1SIRT3SIRT5PDE4A | |
| SCHEMBL837105 | 0.84 | ADORA1 (0.48) | ADORA1ADORA2BADORA2ASIRT1SIRT3 | |
| SCHEMBL13247926 | 0.83 | ADORA2B (0.53) | ADORA1ADORA2BADORA2AADORA3SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| EP-2272848-A1 | Xanthine derivatives as selective HM74A agonists | Glaxosmithkline LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | ADORA1 29/4885ADORA2B 94/4885ADORA2A 16/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | ADORA1 24/4885ADORA2B 97/4885ADORA2A 11/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | ADORA1 32/4885ADORA2B 111/4885ADORA2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.